Compare Novavax Inc (NVAX) vs Peloton Interactive Inc (PTON) Price & Performance

Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.

The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.

Peloton Interactive (PTON) trades at $5.56, down 0.71% on the day, reflecting ongoing investor caution despite achieving its first annual net profit in fiscal 2026. Technical indicators are bearish, with the stock near key support at $5. The company shows improving fundamentals, with net income turning positive and operating cash flow strengthening to $333 million in 2025, though revenue declines persist.

The outlook is mixed: profitability improvements and a 50% analyst buy rating offer potential upside, but subscriber losses, high debt, and bearish technical trends pose significant risks. Investors should weigh the turnaround progress against persistent revenue headwinds and negative shareholder equity.